Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Thorn

Cardiovascular Disease Arlington, VA Medical Doctor

NPI 1932240900 CMS profile 178991

1625 N George Mason Dr, Suite 354, Arlington, VA 22205

Open in the dashboard

General payments

$9,209

463 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Thorn of Arlington, VA is reported in the CMS Open Payments database as having received $9,209 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,390 64
2024 General $1,336 69
2023 General $1,778 81
2022 General $1,666 81
2021 General $1,013 56
2020 General $834 45
2019 General $1,192 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Thorn
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Eric Thorn were reported at $1,390. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Eric Thorn Cardiovascular Disease median Middle half National median
2019 $1,192 $450 $127–$1,392 $163
2020 $834 $242 $77–$751 $114
2021 $1,013 $335 $101–$1,037 $132
2022 $1,666 $395 $121–$1,211 $149
2023 $1,778 $443 $136–$1,283 $160
2024 $1,336 $450 $136–$1,323 $164
2025 $1,390 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $980 48 payments
  2. Novartis Pharmaceuticals Corporation $971 50 payments
  3. Pfizer Inc. $957 54 payments
  4. Amgen Inc. $814 39 payments
  5. Novo Nordisk Inc $547 25 payments
  6. Janssen Pharmaceuticals, Inc $518 26 payments
  7. AstraZeneca Pharmaceuticals LP $510 25 payments
  8. E.R. Squibb & Sons, L.L.C. $465 24 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $389 31 payments
  10. Merck Sharp & Dohme Corporation $368 19 payments
  11. Other $2,689 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,181 461 payments
  2. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE $783 38 payments
  2. Repatha $772 37 payments
  3. ELIQUIS $728 42 payments
  4. XARELTO $518 26 payments
  5. CAMZYOS $419 21 payments
  6. VYNDAQEL $413 23 payments
  7. ENTRESTO $393 22 payments
  8. LEQVIO $392 20 payments
  9. VERQUVO $390 20 payments
  10. LifeVest $389 31 payments
  11. Other $5,644 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,437

Median for Cardiology: 2,533

Drug cost

$490,447

Median for Cardiology: $485,213

Branded share of claims

34.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 91 $123,383
Eliquis Apixaban Brand 85 $113,597
Mounjaro Tirzepatide Brand 47 $70,454
Jardiance Empagliflozin Brand 35 $52,081
Entresto Sacubitril/Valsartan Brand 37 $44,567
Xarelto Rivaroxaban Brand 17 $26,099
Repatha Sureclick Evolocumab Brand 19 $22,283
Brilinta Ticagrelor Brand 18 $21,117
Rosuvastatin Calcium Generic 112 $1,956
Ezetimibe Generic 53 $1,503

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$141,625

Medicare's payments for the services billed

Medicare patients

2,165

Average age 78

Services billed

4,401

1,164 women, 1,001 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 48%
Diabetes 34%
Atrial fibrillation 34%
Chronic kidney disease 32%
Heart failure 30%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $167
$167 37 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $153
$153 — —
Wegovy
  • Novo Nordisk Inc $138
$138 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $117
$117 35 —
ELIQUIS
  • PFIZER INC. $65
$65 85 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record